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Background: It is difficult to study the mechanisms of the metabolic syndrome in humans due to the
heterogeneous genetic background and lifestyle. The present study investigated changes in the gene and protein
profiles in an animal model of the metabolic syndrome to identify the molecular targets associated with the
pathogenesis and progression of obesity related to the metabolic syndrome.
Methods: We extracted mRNAs and proteins from the liver tissues of 6- and 25-week-old spontaneously
hypertensive/NIH –corpulent rat SHR/NDmcr-cp (CP), SHR/Lean (Lean) and Wistar Kyoto rats (WKY) and performed
microarray analysis and two-dimensional difference in gel electrophoresis (2D-DIGE) linked to a matrix-assisted laser
desorption ionization time-of-flight tandem mass spectrometry (MALDI-TOF/TOF MS).
Results: The microarray analysis identified 25 significantly up-regulated genes (P< 0.01; log10 > 1) and 31
significantly down-regulated genes (P< 0.01; log10 <−1) in 6- and 25-week-old CP compared with WKY and Lean.
Several of these genes are known to be involved in important biological processes such as electron transporter
activity, electron transport, lipid metabolism, ion transport, transferase, and ion channel activity. MALDI-TOF/TOF MS
identified 31 proteins with ±1.2 fold change (P< 0.05) in 6- and 25-week-old CP, compared with age-matched WKY
and Lean. The up-regulated proteins are involved in metabolic processes, biological regulation, catalytic activity, and
binding, while the down-regulated proteins are involved in endoplasmic reticulum stress-related unfolded protein
response.
Conclusion: Genes with significant changes in their expression in transcriptomic analysis matched very few of the
proteins identified in proteomics analysis. However, annotated functional classifications might provide an important
reference resource to understand the pathogenesis of obesity associated with the metabolic syndrome.
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The World Health Organization (WHO) has reported that
once considered a problem only in high income countries,
overweight and obesity are now dramatically on the rise in
low- and middle-income countries, particularly in urban
settings [1]. Overweight and obesity related to the meta-
bolic syndrome are also major risk factors for a number of* Correspondence: saho@gene.mie-u.ac.jp
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reproduction in any medium, provided the orchronic diseases, including diabetes, cardiovascular dis-
eases, and cancer [2,3]. The metabolic syndrome is
defined as a cluster of abdominal obesity, atherogenic dys-
lipidemia (hypertriglyceridemia, hypo-HDL cholesterole-
mia, both foster plaque buildup in arterial walls),
hypertension, and hyperglycemia (the body cannot prop-
erly use insulin or blood sugar) [4]. The etiology of the
metabolic syndrome is complex, and is determined by the
interplay of both genetic and environmental factors [5].
Several environmental factors, including smoking, high-
calorie diet, and physical inactivity influence the develop-
ment of the metabolic syndrome [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(SHR/NDmcr-cp) is a new genetically obese strain that
spontaneously develops hypertension, hyperlipidemia,
and non-insulin-independent diabetes mellitus [7]. The
SHR/NDmcr-cp is a sub-strain of the SHR/N-cp. It has
a genetic background from the spontaneously hyperten-
sive rat (SHR) and carries nonsense mutation of leptin
receptor derived from obese Koletsky rat [8]. Since the
phenotype of the SHR/NDmcr-cp is similar to that of
patients with the metabolic syndrome, the SHR/NDmcr-
cp is thought to be one of the most suitable animal
models of the metabolic syndrome [9]. Given that study-
ing SHR/NDmcr-cp would help to clarify some of the
pathophysiological mechanisms of this syndrome, we
used this rat model of the metabolic syndrome in the
present study.
Using microarray and proteomics analyses, the present
study was designed to identify genes and proteins in the
liver tissues with altered expression in the SHR/NDmcr-
cp rats and to find possible molecular targets associated
with the pathogenesis or progression of obesity related
to the metabolic syndrome.
Methods
Animals
SHR/NDmcr-cp (cp/cp) (CP), SHR/Lean (Lean), and
Wistar Kyoto rats (WKY) were purchased from the Dis-
ease Model Cooperative Research Association (Kyoto,
Japan) and used for this study at 6- and 25-weeks of age.
All animals were fed normal diet and housed in a
temperature-controlled environment (25°C) with a 12-
hour light–dark cycle. The investigation conformed to
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996) and was approved
by the Committee on Laboratory Animals Utilization of
Mie University.
Measurement of blood pressure and biochemical tests
Systolic blood pressure (SBP) was measured in six con-
scious rats per group by the tail-cuff method as
described previously [10]. Blood was collected from
anesthetized rats, transferred to a chilled tube containing
heparin, and centrifuged. Plasma was stored at −80°C
until analysis. Serum levels of triglyceride, total-
cholesterol, and glucose were measured at SRL (Tokyo,
Japan) (n= 6 for 6- and 25-week-old rats).
Preparation of RNA and microarray analysis
The liver tissues were obtained from 6- and 25-week-old
rats (n = 6, each), immediately frozen in liquid nitrogen,
and stored at −80°C. Total RNA was extracted from
about 250 mg of liver tissue using the RNeasy Mini Kit
(Qiagen, Valencia, CA) according to the instructionsprovided by the manufacturer. Total RNA concentration
was quantified by spectrophotometry (ND-1000, Nano-
Drop Technologies, Wilmington, DE). Then, a search
for genome-wide expression changes was conducted
using oligo nucleotide microarray (Whole Rat Genome
microarray 22 K, Agilent Technologies, Santa Clara, CA)
in 1) WKY and CP at 6 weeks of age, 2) Lean and CP at
6 weeks of age, 3) WKY and CP at 25 weeks of age, and
4) Lean and CP at 25 weeks of age. Two microarray
slides were used for each comparison in two different
RNA samples from each strain.
Hybridization and microarray scanning
Reverse transcription labeling and hybridization were
conducted using the Agilent 60-mer Oligo microarray
(Agilent Technologies), according to the instructions
provided by the manufacturer. Briefly, total RNA of
500 ng prepared from the individual rat liver tissue sam-
ples was used for cDNA synthesis using a T7 promoter
primer with Agilent low RNA input fluorescent linear
amplification kit. The cRNA was synthesized using T7
RNA polymerase. The reaction was carried out in a solu-
tion containing 50 mM dATP/dGTP/dTTP, 25 mM
dCTP, 25 mM cyanine 3 (Cy3)-dCTP (for WKY or Lean
sample) or cyanine 5 (Cy5)-dCTP (for CP sample)
(NEL580 and 581, Perkin Elmer Life Science, Waltham,
MA) and 400 U MMLV reverse transcriptase at 42°C for
1 hr. The labeled cRNA samples were purified using
Qiagen’s RNA mini spin columns. Every cyanine-labeled
cRNA (0.75 μg) was individually hybridized to a rat Agi-
lent Oligo 22 k microarray slide. Hybridization was car-
ried out in 22 mL of a hybridization mixture containing
cDNA probes at 65°C for 17 hr. The glass slides were
then washed with 0:5 × SSC and 0.01% sodium dodecyl
sulfate (SDS) at room temperature for 5 min, and with
0:06 × SSC at room temperature for 2 min. Immediately
after removing the wash buffer by centrifugation, the
glass slides were scanned with an Agilent DNA Micro-
Array Scanner (Agilent Technologies) containing a
532 nm laser for Cy3 measurement and a 635 nm laser
for Cy5 measurement.
Quantitative RT-PCR analysis
To confirm the results of microarray analysis, total RNA
extracted from the liver tissue was subjected to quantita-
tive reverse transcription and polymerase chain reaction
(RT-PCR) analysis with primers specific for mRNAs en-
coding ELOVL family member 6, elongation of long
chain fatty acids (Elovl6) and fatty acid synthase (Fasn)
(n= 6 for 6- and 25-week-old rats). Amplification was
carried out in a reaction volume of 25 μl, containing:
12.5 μl of FastStart Universal Probe Master (2 ×) (Roche
Applied Science, Mannheim, Germany), 200 nM of each
primer, 100 nM of Universal ProbeLibrary probe (Roche
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cycling was initiated with 2 min incubation at 50°C, fol-
lowed by 10 min denaturation at 95°C. Then 40 cycles of
95°C for 15 s and 65°C for 60 s were applied. The
mRNA for β-actin was used as an internal control.
Preparation of protein samples
Frozen liver tissues were also homogenized in lysis buffer
(30 mM Tris–HCl, 7 M urea 2 M thiourea, 4% w/v
CHAPS, and a protease inhibitor cocktail, pH 8.5). After
incubation for 60 min on ice, homogenates were centri-
fuged at 30,000 × g for 30 min at 4°C and the supernatant
was collected. Protein concentration was determined in
the supernatant by the Bradford assay (Bio-rad Laborator-
ies, Hercules, CA), using bovine serum albumin as a
standard [11].
Two-dimensional fluorescence difference gel
electrophoresis (2D-DIGE)
For 2D-DIGE, 25 μg of each sample were labeled with 200
pmol of amine-reactive cyanine dyes, Cy3 or Cy5 devel-
oped for fluorescence 2D-DIGE technology (GE Health-
care, Buckinghamshire, UK) (n=4 for 6- and 25-week-old
rats) [12]. Internal pools were generated by combining
equal amounts of all samples and were labeled with Cy2.
Then, two-dimensional gel electrophoresis (2DE) was per-
formed, as described previously [13]. After 2DE, cyanine-
labeled proteins were visualized directly by scanning,
using the Typhoon 9400 imager (GE Healthcare) in fluor-
escence mode. The differential in-gel analysis module of
the DeCyder software (GE Healthcare) was used for auto-
matic detection followed by editing of protein spots. The
same software was used for abundance measurements for
each gel by comparing normalized volume ratios of indi-
vidual spots from Cy3- or Cy5-labeled samples to corre-
sponding Cy2-signals from the pooled samples (internal
standard) [14]. Thereafter, all gel comparisons and initial
screening type statistical analyses were performed with the
biological variation analysis module.
Protein identification
After image analysis, gels containing the additional load
of unlabeled proteins from the liver tissues were stained
with Colloidal Coomassie Brilliant Blue G (GE Health-
care) and matched to the fluorescent 2D-DIGE images.
Selected spots were picked and in-gel digestion of pro-
tein samples was performed using the protocol described
in detail previously [13,15]. Mass analysis of peptide
mixtures was performed using a matrix-assisted laser de-
sorption ionization time-of-flight tandem mass spec-
trometry (MALDI-TOF/TOF MS; 4800 Plus MALDI
TOF/TOFTM Analyzer, Applied Biosystems, Foster City,
CA) operating in positive-ion reflector mode. The Para-
gon Method was applied for protein database search,using Protein Pilot software (Applied Biosystems) to
identify excised proteins.
Western blot analysis
To confirm the results of proteomic analysis, western
blot analysis was conducted. Samples (n= 4 in each
group) containing 10 μg of liver tissue proteins were
separated by 12% SDS-PAGE and electroblotted onto
polyvinylidene difluoride (PVDF) membranes. The mem-
branes were incubated with rabbit polyclonal antibodies
to mouse 10-formyltetrahydrofolate dehydrogenase
(FTHFD) (Abcam, Cambridge, UK) at a 1:10,000 dilution
and to human carbonic anhydrase III (CA3) (Abcam) at
a 1:1,000 dilution. The formed immunocomplexes were
visualized by enhanced chemiluminescence (GE Health-
care) using ChemiDox XRS-J (Bio-rad Laboratories).
Mouse anti-β-actin monoclonal antibody (Sigma, St
Louis, MO) at a 1:10,000 dilution was used as a loading
control. The density of the bands was quantified by
Quantity One v3.0 software (Bio-rad Laboratories). Pro-
tein expression levels were normalized relative to the
level of β-actin protein in the same tissue sample.
Statistical analysis
Microarray data analysis was carried out using Gene-
Spring ver. 7.3.1 software (Agilent Technology) [16,17].
The detected signals were normalized using GeneSpring
normalization algorithms. In each comparison, genes were
filtered based on minimum ±1.0 of log ratio (WKY vs. CP
or Lean vs. CP) and P< 0.01 using Student’s test. Gene
ontology (GO) analysis was performed using GeneSpring
(Agilent Technology). With regard to the data of proteo-
mics analysis, the differential in-gel analysis module of the
DeCyder software (GE Healthcare) was used for automatic
detection of protein spots and for abundance measure-
ments of each gel by comparing the normalized volume
ratios of individual spots [14]. Two-tailed Student’s t-test
was performed to determine the differences between
paired groups (WKY vs. CP or Lean vs. CP) using the bio-
logical variation analysis module of DeCyder software (GE
Healthcare). Data are presented as mean±SEM. Differ-
ences among physiological and biochemical parameters
and the quantitated data of both RT-PCR and western blot
analyses were evaluated for statistical significance by one-
way analysis of variance followed by Dunnett’s post hoc
test. Statistical analyses were performed using the JMP 8.0
software (SAS Institute Inc., Cary, NC). A P value of < 0.05
was considered statistically significant.
Results
Changes in body weight, systolic blood pressure, and
biochemical parameters
Body weight and liver weight were significantly greater
in CP than in WKY and Lean at 6 and 25 weeks of age
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6 weeks of age, and there was no significant difference
in systolic blood pressure at the two ages between CP
and Lean (Table 1). At 6 weeks of age, there was no sig-
nificant difference in triglyceride and glucose levels
among the three groups, however, at 25 weeks of age,
these levels were significantly higher in CP than in both
WKY and Lean (Table 1). These results indicate the de-
velopment of early stages of the metabolic syndrome at
6 weeks of age and the chronic stage of the syndrome at
25 weeks of age in CP. There were no significant differ-
ences in triglyceride and glucose levels between WKY
and Lean at the two ages (Table 1). Therefore, we used
WKY and Lean as the controls to identify the possible
molecular targets associated with the pathogenesis or
progression of obesity associated with the metabolic
syndrome.
Gene expression profiles by microarray analysis
After the experiments of microarray analysis, all
hybridization spots on the image were quantified. The
data of the fluorescence intensity were converted into
log10 values. Genes with significantly different expres-
sion levels (P < 0.01), relative to WKY and Lean, were
extracted for further analysis. On the oligoDNA micro-
array, 253 and 125 genes were significantly up-
regulated (P < 0.01 and log10 > 1) in 6-week-old CP
compared with age-matched WKY and Lean. Further-
more, 244 and 97 genes were down-regulated (P < 0.01
and log10 <−1) in 6-week-old CP compared with age-
matched WKY and Lean. We also found 163 and 149
significantly up-regulated genes and 184 and 162
down-regulated genes in 25-week-old CP compared
with 25-week-old WKY and Lean. Among these,
25 genes were significantly up-regulated (Additional
file 1: Table S1) and 31 genes were significantly down-
regulated (Additional file 1: Table S2) in the liver
tissues of 6- and 25-week-old CP, compared with age-
matched WKY and Lean. The results of microarray
analysis were confirmed by quantitative RT-PCR ana-
lysis. The mRNA levels of Elovl6 and Fasn were greaterTable 1 Body and liver tissue weights, blood pressure, and bi
6 weeks of age
WKY Lean C
Body weight (g) 140.2 ± 1.1 147.5 ± 1.2 2
Liver weight (g) 7.2 ± 0.9 7.5 ± 0.6
Blood pressure (mmHg) 101.5 ± 1.2 179.5 ± 1.4* 1
Triglyceride (mg/dl) 65.8 ± 7.7 65.2 ± 3.7
Non-fasting glucose (mg/dl) 178.4 ± 7.9 173.7 ± 7.6 1
Data are mean ± SEM of six rats per group.
*P < 0.05, compared with the corresponding value for WKY;
† P < 0.05, compared with the corresponding value for Lean.
WKY; Wistar Kyoto rats, Lean; spontaneously hypertensive rats (SHR/lean), CP; SHR/Nin of 6- and 25-week-old CP, compared with age-
matched control (WKY and Lean) (Additional file 2:
Figure S1).
Functional categories of genes with altered expression
in CP
To understand their biological roles, the genes with sig-
nificant changes in expression detected in CP by micro-
array analysis were assigned to established GO
classification by GeneSpring ver. 7.3.1. In GO classifica-
tion, we found three aberrant GO terms (p < 0.01) in up-
regulated genes, electron transporter activity, electron
transport, and lipid metabolism and five GO terms
(p < 0.01) in down-regulated genes electron transporter
activity, electron transport, ion transport, transferase,
and ion channel activity (Table 2). For the results of
Kyoto Encyclopedia of Genes and Genomes (KEGG)
molecular pathway analysis, genes with significant
change in expression in CP by microarray analysis were
also assigned to KEGG molecular pathway by Gene-
Spring. In KEGG molecular pathway analysis, 10 or 6
predicted pathways were found in the up-regulated and
down-regulated genes, respectively (Table 2). The genes
with significant change in expression in CP by micro-
array analysis were also imported into the PANTHER
database. The PANTHER classification system indicated
that the up-regulated and down-regulated genes in CP
can be classified into eight groups according to their
functional properties: 1) lipid metabolism, 2) carbohy-
drate metabolism, 3) protein metabolism, 4) cellular
amino acid metabolism, 5) immune system, 6) cell adhe-
sion, 7) signal transduction, and 8) others (Additional
file 1: Table S1 and Additional file 1: Table S2).
Identification of proteins with significant change in
expression levels
To investigate the changes in protein expression levels in
the liver, proteins extracted from the liver tissues of 6- and
25-week-old WKY, Lean, and CP were subjected to com-
parative analysis by 2D-DIGE. From approximately 2000
(2295) spots detected in each gel, 307 protein spots wereochemical data in 6- and 25-week-old rats
25 weeks of age
P WKY Lean CP
28.5 ± 1.3*† 422.8 ± 5.2 413.9 ± 4.1 578.4 ± 6.8*†
12.5 ± 1.1*† 12.8 ± 1.2 13.9 ± 1.1 28.4 ± 2.8*†
73.3 ± 1.2* 108.7 ± 1.8 208.7 ± 2.1* 191.2 ± 4.0*
93.3 ± 13.1 62.8 ± 12.5 61.8 ± 5.5 816.3 ± 51.6*†
89.2 ± 4.0 160.7 ± 5.9 186.2 ± 34.5 278.2 ± 26.7*†
Dmcr-cp (cp/cp).
Table 2 List of entities identified by GO and the
pathways identified by KEGG of significantly
up-regulated and down-regulated genes in liver tissues
in 6- and 25-week-old CP
GO accession GO Term P value
Up-regulation
GO:0005489 electron transporter activity 7.31E-06
GO:0006118 electron transport 7.42E-06
GO:0006629 lipid metabolism 5.07E-05
Down-regulation
GO:0005489 electron transporter activity 1.00E-03
GO:0006118 electron transport 1.01E-03
GO:0006811 ion transport 1.55E-03
GO:0010740 transferase 3.29E-03
GO:0005216 ion channel activity 4.86E-03
Predicted pathway P value
Up-regulation
Carbon fixation 2.54E-06
Pentose phosphate pathway 1.86E-04
Pyruvate metabolism 4.07E-04
Glutathione metabolism 4.07E-04
Fructose and mannose metabolism 5.27E-04
Metabolism of xenobiotics by cytochrome P450 7.61E-04
Fatty acid metabolism 9.78E-04
Glycolysis-Gluconeogenesis 1.04E-03
Arachidonic acid metabolism 1.49E-03
Fatty acid biosynthesis 5.44E-03
Down-regulation
gamma-hexachlorocyclohexane degradation 6.48E-07
Metabolism of xenobiotics by cytochrome P450 7.14E-06
Linoleic acid metabolism 2.36E-06
PPARγ signaling pathway 2.78E-03
Methionine metabolism 7.57E-03
Glyoxylate and dicarboxylate metabolism 7.57E-03
PPARγ: peroxisome proliferator-activated receptor γ.
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age-matched WKY and Lean, whereas 407 spots were
found to be modified in 25-week-old rats. Among these,
63 spots were significantly modified in 6- and 25-week-old
CP according to the DeCyder software analysis with an
absolute ratio of more than 1.2-folds (p< 0.05), compared
with age-matched WKY and Lean.
These differential spots were cut from the gels,
digested and applied to MALDI-TOF-MS analysis. The
latter identified 31 spots (Figure 1), which included 13
spots with significantly up-regulated expression in
6- and 25-week-old CP, compared with age-matched
WKY and Lean (Table 3), and 18 spots significantlydown-regulated in 6- and 25-week-old CP, compared
with age-matched WKY and Lean (Table 3). The peptide
mass peaks were compared with those in the protein
database using Paragon Method. Western blot analysis
was also performed to confirm the results of proteomics
analysis and the findings (Additional file 2: Figure S2A)
were consistent with those of proteomic results; the ex-
pression of FTHFD was significantly up-regulated while
that of CA3 was significantly down-regulated in 6- and
25-week-old CP compared with age-matched control
(WKY and Lean) (Additional file 2: Figure S2B).
Functional categories of protein with altered expression
in CP
To functionally annotate the identified proteins, we
mapped them to GO at three levels: cellular component,
biological process, and molecular function (Figure 2).
The cellular component GO annotation revealed that
most of the up-regulated GO annotated proteins were
located at the mitochondrion while half of the down-
regulated proteins were located at the endoplasmic
reticulum (ER) (Figure 2A). The GO annotation for bio-
logical process showed that the up-regulated proteins
were mainly involved in metabolic processes (Figure 2B).
Furthermore, mapping for the molecular function
showed that half of the up-regulated proteins belonged
to catalytic activity and more than half of the down-
regulated proteins belonged to binding (Figure 2C).
To understand their biological roles, proteins with sig-
nificant changes in their expression by proteomics analysis
were also imported into the PANTHER database. The
PANTHER classification system indicated that the up-
regulated and down-regulated genes in CP can be classi-
fied into six groups according to their functional proper-
ties: 1) lipid metabolism, 2) carbohydrate metabolism, 3)
protein metabolism, 4) Nucleic acid metabolism, 5) im-
mune system process, and 6) others (Additional file 1:
Table S3). Additional file 1: Table S3 also shows the log
ratio change of gene expression determined by microarray
analysis for proteins identified by proteomics analysis in
6- and 25-week-old CP and age-matched control (WKY
and Lean) rats.
Discussion
Microarray analysis is a powerful tool for the evaluation
of expression of many genes in various experimental
systems and is particularly suited for the identification
of target genes for transcription factors [18]. In the
present study, we investigated simultaneous changes in
gene and protein profiles using the metabolic syndrome
rat model to identify the potential molecular targets
associated with obesity- metabolic syndrome. The
results of microarray and 2D-DIGE linked to MALDI-




























































Figure 1 A representative 2D-DIGE image of liver lysates from 25-week-old Lean and CP. (A) The proteins (40 μg each) were labeled
with Cy3 and Cy5 dyes, mixed and subjected to 2D-DIGE analysis. We selected significantly different spots of 6- and 25-week-old CP, relative to
age-matched control (WKY and Lean) rats. The representative 12 quantified expression levels of each strain at 6 (B) and 25 weeks of age (C) were
expressed as mean± SEM from four rats per group. *P< 0.05, compared with the corresponding value for WKY or Lean.
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chronic stages of the metabolic syndrome.
In both microarray and proteomics analyses, the only
significant change in 6- and 25-week-old CP, compared
with the age-matched controls, was in sulfotransferase
family 1C, membrane 1 (SULT1C1). SULT1C1 is
expressed in the liver, lung, and intestine [19]. One sub-
family of this enzyme, estrogen SULT, is expressed in sub-
cutaneous adipose tissue and plays potential roles in
glucose homeostasis and inflammation [20,21]. The mem-
bers of this enzyme are reported to play important roles in
not only the metabolism of drugs and xenobiotics but also
the biotransformation of a variety of endogenous com-
pounds [22]. Although the enzymatic properties and func-
tional relevance of SULT1C1 remain unknown, SULT1C1
gene expression is reported to be down-regulated inisolated primary hepatocytes from livers of obese insulin-
resistant Zucker rats [23], consistent with our results. In
the present study, only a few of the genes with significant
changes in microarray analysis were found to show
matching change in the expression of their proteins in
proteomics analysis (Tables 3, Additional file 1: Table S1
and Additional file 1: Table S2). Previous studies using
high-throughput technologies (transcriptomic and proteo-
mics analyses) demonstrated a positive correlation be-
tween transcript and protein levels for the majority of
molecules [24,25]. Other studies, however, reported lim-
ited correlation between transcription and translation in
mammals [26]. In the present microarray analysis, we only
used genes with significant up-regulation (P< 0.01; log10
>1) or down-regulation (P< 0.01; log10 <−1) in 6- and 25-
week-old CP, compared with WKY and Lean. Among the
Table 3 List of liver tissue proteins with significant spot changes identified in 6- and 25-week-old CP
Spot
no.




WKY-CP Lean-CP WKY-CP Lean-CP
Up-regulated proteins
458 Pyruvate carboxylase 3.1 3 1.15 1.15 1.27 1.22
561 Staphylococcal nuclease domain-containing protein 1 6.4 5 1.41 1.43 2.19 2.35
575 10-formyltetrahydrofolate dehydrogenase 12.4 7 2.35 2.54 2.25 2.13
579 10-formyltetrahydrofolate dehydrogenase 10.3 5 1.91 1.89 1.96 1.84
595 Dimethylglycine dehydrogenase 8.3 4 1.22 1.27 1.55 1.77
894 Dihydrolipoyllysine-residue acetyltransferase component
of pyruvate dehydrogenase complex
9.7 3 1.46 1.59 2.61 2.85
1221 Glutathione synthetase 19.2 5 1.2 1.28 1.64 1.56
1559 Glycerol-3-phosphate dehydrogenase [NAD+] 21 6 1.16 1.16 1.77 1.54
1568 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 25.6 6 1.35 1.37 2.31 1.91
1604 Pyruvate dehydrogenase E1 component subunit beta 25.4 7 1.18 1.25 1.6 1.68
1613 Malate dehydrogenase 15 5 1.43 1.43 1.81 1.8
1666 Ketohexokinase 30.2 6 1.2 1.19 1.51 1.42
1925 Glutathione S-transferase kappa 1 9.3 2 1.57 1.6 1.93 1.6
Down-regulated proteins
273 Hypoxia up-regulated protein 1 17 5 −1.53 −1.42 −1.55 −1.35
593 Endoplasmin 12.7 8 −1.75 −1.73 −1.76 −1.68
789 Protein disulfide-isomerase A4 8.6 5 −1.5 −1.42 −1.54 −1.49
819 78 kDa glucose-regulated protein 14.3 6 −1.39 −1.27 −1.69 −1.47
820 78 kDa glucose-regulated protein 18.5 8 −1.44 −1.27 −1.82 −1.61
955 Alpha-2-HS-glycoprotein 15.3 3 −1.27 −1.2 −2.75 −3.15
1016 Calreticulin 33.2 9 −1.47 −1.39 −1.6 −1.5
1037 Protein disulfide-isomerase A3 19.4 6 −1.31 −1.23 −1.53 −1.42
1053 Protein disulfide-isomerase A3 14.7 5 −1.41 −1.28 −1.52 −1.48
1217 Keratin, type I cytoskeletal 18 11.1 4 −1.52 −1.44 −1.61 −1.63
1499 Farnesyl pyrophosphate synthase 9.9 3 −1.24 −1.22 −1.83 −1.76
1598 Regucalcin 24.4 7 −1.27 −1.19 −1.7 −1.85
1620 Sulfotransferase 1C1 30.3 6 −1.87 −1.71 −1.54 −1.48
1840 C-reactive protein 8.7 6 −1.23 −1.23 −1.89 −1.7
1860 Carbonic anhydrase 3 51.5 10 −4.27 −4.84 −2.12 −2.36
1862 Carbonic anhydrase 3 43.5 8 −2.69 −3.24 −1.72 −1.97
2082 Major urinary protein 37.6 6 −2.42 −2.64 −3.34 −3.48
2164 Cytochrome b5 55.2 7 −1.18 −1.18 −1.68 −1.52
Abbreviations as in Table 1.
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pression of 15 proteins was up-regulated or down-
regulated by more than 1.5 fold in 6- and 25-week-old CP,
compared with WKY and Lean (Additional file 1: Table
S3). The different expression patterns noted in the two
methodological approaches might arise from limitation of
detection sensitivity or electrophoretic separation. More-
over, the discrepancy between the microarray andproteomics analyses might be due to differential regulation
of translation, turnover, or alternative splicing.
The cellular component GO annotation revealed that
the up-regulated GO annotated proteins were located in
the mitochondria (90%) while the down-regulated pro-
teins were mapped to the ER (65%). Our study showed
down-regulation of both CRT and PDIA3/4. CRT is a
highly versatile lectin-like chaperone involved in many
Up-regulated proteins                           Down-regulaed proteins
cellular metabolic process biosynthetic process
biological regulation response to stimulus
carbohydrate metabolic process carboxylic acid metabolic process
response to stimulus biological regulation
cellular metabolic process small molecule metabolic process







endoplasmic reticlum extracellular matrix cytosol
mitochondrion cytoplasm
transferase activity oxidoreductase activity
protein binding nucleotide binding
ion binding
Molecular function
ion binding protein binding
oxidoreductase activity nucleotide binding
electron carrier activity transferase activity
Figure 2 Gene Ontology (GO) annotation of identified proteins. The graphs show the percentages of corresponding GO terms to the total
number of annotated proteins. The identified up-regulated or down-regulated proteins were mapped to GO at the three levels: cellular
component (A), biological process (B), and molecular function (C).
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[27]. The CRT-associated functions include acting as
chaperone of nascent glycoproteins, regulator of Ca2+
homeostasis, cell adhesion, and inhibition of angiogen-
esis and tumor growth [28]. A highly adipogenic signal
was detected in embryonic stem cells from Crt-deficient
mice [29] and high glucose uptake and glycogen depos-
ition were described in ventricular cardiomyocytes of
these mice [30]. Crt deficiency also correlated with sig-
nificant increases in insulin receptor expression, stability
of glucose transporter 1 (GLUT1) expression, and in
insulin-stimulated Akt phosphorylation and kinase activ-
ity, suggesting that the lack of CRT is associated with
changes in insulin signaling and glucose metabolism
[31-33]. While the potential effects of PDIA3 and PDIA4
are unknown, oxidative folding of glycoproteins in the
ER and/or interaction with calnexin (CNX) and CRT
could be affected [34]. PDI acts as a chaperone to pro-
mote oxidative refolding of non-monoglycosylated and
reduces denatured lysozymes in the absence of CNX/
CRT in vitro [35]. Furthermore, PDI is reported to inter-
act with a specific set of glycoproteins that are recruited
via its interactions with the lectins CNX/CRT [36,37].
ER stress has recently been implicated in the patho-
physiology of obesity-related insulin resistance; however,
what causes ER stress in obesity remains uncertain [38].
In our study, significant down-regulation of CRT and
PDIA3/4 was noted in CP compared with WKY and
Lean. Since the proteins involved in ER stress-related
unfolded protein response were down-regulated, they
may induce resistance to insulin and play an important
role in the development of obesity associated with the
metabolic syndrome.
Conclusion
In the present study, we applied comparative genomic
and proteomic analyses to identify the molecular targets
in liver tissue associated with obesity of the metabolic
syndrome. Microarray analysis identified 25 significantly
up-regulated genes and 31 significantly down-regulated
genes in the liver tissues of 6- and 25-week-old CP, com-
pared with age-matched WKY and Lean. To gain further
insight into the roles of these genes in biological pro-
cesses, the genes with significantly change in their ex-
pression were classified according to their function. A
large proportion of the genes were involved in electron
transporter activity, electron transport, lipid metabolism,
ion transport, transferase, and ion channel activity. Using
proteomics approach, the up-regulated proteins were
involved in metabolic process, biological regulation, cata-
lytic activity, and binding. On the other hand, the down-
regulated proteins were involved in ER stress-related
unfolded protein response. These findings suggest that
both groups of proteins might contribute to thedevelopment of obesity associated with the metabolic
syndrome. These molecules may provide an important
reference resource and be applied to the development of
therapeutic targets for obesity associated with the meta-
bolic syndrome.
Additional files
Additional file 1: Table S1. List of significantly up-regulated genes
in CP rats, compared with age-matched control rats (WKY and Lean).
Table S2. List of significantly down-regulated genes in CP rats,
compared with the age-matched control rats (WKY and Lean).
Table S3. Comparison of gene expression in microarray analysis of
proteins identified in proteomics analysis.
Additional file 2: Figure S1. Expression of Elovl6 and Fasn in liver
tissues of 6- and 25-week-old WKY, Lean, and CP. Data are expressed
relative to the mRNA expression of β-actin. All quantitative data are
mean± SEM values of six rats per group. *P< 0.05, compared with
6-week-old WKY and Lean; †P< 0.05, compared with 25-week-old WKY
and Lean. Figure S2. Confirmation of the 2D-DIGE results by western
blot analysis. (A) Representative immunoblot analysis of FTHFD, CA3, and
β-actin (loading control) in liver tissues of representative 6- and
25-week-old WKY, Lean, and CP rats. (B) Relative protein expression levels
of FTHFD and CA3 in liver tissues of 6- and 25-week-old WKY, Lean, and
CP. All quantitative data are mean± SEM values of four rats per group.
*P< 0.05, compared with 6-week-old WKY and Lean; †P< 0.05, compared
with 25-week-old WKY and Lean.
Abbreviations
2D-DIGE: Two-dimensional fluorescence difference gel electrophoresis;
CA3: Carbonic anhydrase III; CNX: Calnexin; CRT: Calreticulin; ELOVL6: ELOVL
family member 6, elongation of long chain fatty acids; ER: Endoplasmic
reticulum; FASN: Fatty acid synthase; FTHFD: 10-formyltetrahydrofolate
dehydrogenase; MALDI-TOF/TOF MS: Matrix-assisted laser desorption
ionization time-of-flight tandem mass spectrometry; PDIA A3/4: Protein
disulfide-isomerase A3/4; RT-PCR: Quantitative reverse transcription and
polymerase chain reaction; SBP: Systolic blood pressure; SHR/NDmcr-
cp: Spontaneously hypertensive/NIH –corpulent rat; WKY: Wistar Kyoto rats.
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